At a glance
ClinicalIndex Comparison RecordN/ACompleted· 189 enrolled
Drug / intervention
R3 Biolox Delta Ceramic Acetabular Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - US
In Brief
An observational study evaluating R3 Biolox Delta Ceramic Acetabular System for Degenerative Joint Disease. Completed, enrolled 189 participants across 8 sites.
Detailed Summary
R3 Delta Post-Approval Study U.S.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDegenerative Joint Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartFeb 2018
Primary CompletionMay 2023
TodayJul 2026
First PostedFeb 17, 2017
Enrollment StartFeb 7, 2018
Primary CompletionMay 31, 2023
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 9.4 years ago
Interventions
R3 Biolox Delta Ceramic Acetabular Systemdevice
All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).